SCHEMBL713850

SCHEMBL713850

Cc1ccc(-c2nnc(Nc3ccc(S(=O)(=O)Nc4nccs4)cc3)c3ccccc23)cc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.85
MEN1 O00255 2/20 0.85
KMT2A Q03164 2/20 0.85
KDM4E B2RXH2 2/20 0.81
TDP1 Q9NUW8 2/20 0.81
USP2 O75604 1/20 0.81
PPARG P37231 1/20 0.81
RECQL P46063 1/20 0.81
BLM P54132 1/20 0.81
NCOA2 Q15596 1/20 0.81
NCOA1 Q15788 1/20 0.81
ENPP3 O14638 9/20 0.63
KDR P35968 2/20 0.62
EGFR P00533 1/20 0.62
CA2 P00918 4/20 0.56
CA9 Q16790 4/20 0.56
PPIA P62937 1/20 0.55
TP53 P04637 2/20 0.52
THRB P10828 1/20 0.52
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL711139 0.92 MEN1 (1.00) POLBMEN1KMT2AKDM4ETDP1
SCHEMBL713991 0.90 POLB (0.85) POLBMEN1KMT2AKDM4ETDP1
SCHEMBL713877 0.86 POLB (0.74) POLBMEN1KMT2AKDM4ETDP1
SCHEMBL7918566 0.77 ENPP3 (0.76) POLBMEN1KMT2AKDM4EENPP3
SCHEMBL8388562 0.77 PPIA (0.76) POLBMEN1KMT2AKDM4ETDP1
Hydrochloric Acid SCHEMBL8812502 0.74 HSD17B10 (0.69) POLBMEN1KMT2AKDM4ETDP1
SCHEMBL7904940 0.73 ENPP3 (0.70) POLBKMT2AKDM4EENPP3KDR
SCHEMBL7905029 0.73 NPSR1 (0.73) POLBKMT2AKDM4EENPP3KDR
SCHEMBL713988 0.72 ALDH1A1 (0.64) POLBMEN1KMT2AKDM4ETDP1
SCHEMBL711626 0.71 ALDH1A1 (0.60) POLBMEN1KMT2AKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP claimed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US claimed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A POLB 4439/4885MEN1 4426/4885KMT2A 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.